Clinical Research

A neuroprotectant drug has been shown to protect the human brain against the damaging effects of stroke. The clinical trial was a randomized, double blind, multi-center trial that was conducted in Canada and the USA. The study evaluated the effectiveness of NA-1 (Tat-NR2B9c) when it was administered after the onset of small strokes that are incurred by patients who undergo neurointerventional procedures to repair brain aneurysms. This type of small ischemic stroke occurs in over 90% of aneurysm patients after such a procedure, but usually does not cause overt neurological disability. 

 Apollo Hospitals performed a complex spinal surgery on a 10-year-old child, the 12th successful surgery done within 10 days of the launch of Renaissance Robotic Technology, the only technology specifically designed for spine surgery. Apollo Hospitals Group is the first in the Asia-Pacific to offer this surgical guidance system, which is a minimally-invasive robotic-guided spine surgery. 

A 10-year-old girl from Gujarat, Heema was born with congenital anomalies that left her with a severely deformed spine. Before being admitted to Apollo Hospitals, the child had already undergone multiple procedures that had failed and left her with rods placed in her back, broken at multiple places, and a spine that was grotesquely deformed.

Obesity is not just happening in New York City 7-Elevens(1), it is also happening in aging bones.

Bone marrow stem cells, which are adult stem cells, are in their fifth decade of uncontroversial new discovery. But they can still surprise us.  Our bones may be getting fatter as we age, and it could lead to osteoporosis, the condition where bone mineral density is 2.5 standard deviations below the mean (62%). The NIH estimates that up to 50% of women and 25% of men over the age of 50 will break a bone due to osteoporosis. 

A large study published in Human Reproduction (1) looked at the effect of induced abortions on a subsequent first birth and found that women who have had three or more abortions have a higher risk of adverse birth outcomes, such as delivering premature and low birth weight babies.

Oxford BioMedica plc biopharmaceuticals and its partner Sanofi announced a positive interim review of the RetinoStat(R) Phase I study in neovascular "wet" age-related macular degeneration (AMD) and the StarGen(TM) Phase I/IIa study in Stargardt disease by the Data Safety Monitoring Board (DSMB); an independent panel of specialists in the fields of ophthalmology, virology and vectorology. RetinoStat(R) and StarGen(TM) were designed and developed by Oxford BioMedica using the Company's proprietary LentiVector(R) gene delivery technology. 

Affinium Pharmaceuticals announced today that full recruitment has been achieved in its multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin&skin structure infections ("ABSSSI"). This Phase 2 trial is the first human efficacy study conducted with a new class of antibiotics designed to specifically inhibit staphylococcal fatty acid biosynthesis via a new drug target, the fatty acid synthase II (FASII) system. Results expected in late 2012 will represent a significant proof-of-concept milestone for this unique, Staphylococcus-specific antibiotic, AFN-1252. 

Fainting, also called vasovagal syncope (by about five neurologists and no one else), is a brief loss of consciousness that occurs when blood flow to the brain drops.  Its causes are so numerous that it is basically unknown what causes it - everything from dehydration to medications to pregnancy, heart conditions and age - but these triggers all occur among people who have a strong genetic predisposition, according to new research.

For most of our lives; physicians, hospitals, and insurance companies have used paper medical records. They controlled the flow of data, but allowed patients and others access to their records.